Download PDF
Thromb Haemost 2002; 87(06): 1084
DOI: 10.1055/s-0037-1613141
Letters to the Editor
Schattauer GmbH

Correlation of Activated Clotting Time (ACT) with rFVIIa Infusion and Clinical Efficacy in a Patient with Glanzmann Thrombasthenia and Platelet Alloantibodies

Afshin Ameri
1   Division of Pediatric Hematology/Oncology, University of Louisville; Novo Nordisk Pharmaceuticals, Inc., USA
,
Scott Stolte
1   Division of Pediatric Hematology/Oncology, University of Louisville; Novo Nordisk Pharmaceuticals, Inc., USA
› Author Affiliations
Further Information

Publication History

Received 22 January 2002

Accepted 25 January 2002

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-95.
    PubMedGoogle Scholar
  • 2 Bierhng P, Fromont P, Elbez A, Duedari N, Kieffer N. Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient. Vox Sanguinis 1998; 55: 109-13.
    PubMedGoogle Scholar
  • 3 Ito K. et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann’s thrombasthenia and multiple anti-platelet antibodies. Vox Sanguinis 1991; 61: 40-6.
    PubMedGoogle Scholar
  • 4 Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3.
    PubMedGoogle Scholar